Olanzapine induced neuroleptic malignant syndrome--a case review

Hum Psychopharmacol. 2003 Jun;18(4):301-9. doi: 10.1002/hup.483.

Abstract

Neuroleptic malignant syndrome is the rarest and the most serious of the neuroleptic induced movement disorders. Although potent neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs may also be a cause of NMS. Three databases were searched using the terms 'olanzapine' and 'neuroleptic' 'malignant syndrome'. Case reports were selected and reviewed from among all articles that fulfilled the search criteria. Twenty six cases were reviewed. Twenty cases fulfilled the criteria published by Sachdev et al. Olanzapine was the most probable cause of NMS in 16 cases. The absence of rigidity was described in only two of 16 highly probable olanzapine induced NMS cases, which is not as often as it is reported in clozapine associated NMS (36%). It was found that prior NMS is an important risk factor in NMS.

Publication types

  • Review

MeSH terms

  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / pharmacology
  • Benzodiazepines
  • Humans
  • Neuroleptic Malignant Syndrome / etiology*
  • Olanzapine
  • Pirenzepine / adverse effects*
  • Pirenzepine / analogs & derivatives*
  • Pirenzepine / pharmacology
  • Schizophrenia / drug therapy

Substances

  • Antipsychotic Agents
  • Benzodiazepines
  • Pirenzepine
  • Olanzapine